Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial( )

BACKGROUND: Therapies for refractory cytomegalovirus infections (with or without resistance [R/R]) in transplant recipients are limited by toxicities. Maribavir has multimodal anti-cytomegalovirus activity through the inhibition of UL97 protein kinase. METHODS: In this phase 3, open-label study, hem...

Descripción completa

Detalles Bibliográficos
Autores principales: Avery, Robin K, Alain, Sophie, Alexander, Barbara D, Blumberg, Emily A, Chemaly, Roy F, Cordonnier, Catherine, Duarte, Rafael F, Florescu, Diana F, Kamar, Nassim, Kumar, Deepali, Maertens, Johan, Marty, Francisco M, Papanicolaou, Genovefa A, Silveira, Fernanda P, Witzke, Oliver, Wu, Jingyang, Sundberg, Aimee K, Fournier, Martha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9464078/
https://www.ncbi.nlm.nih.gov/pubmed/34864943
http://dx.doi.org/10.1093/cid/ciab988

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9464078/
https://www.ncbi.nlm.nih.gov/pubmed/34864943
http://dx.doi.org/10.1093/cid/ciab988

Ejemplares similares